Skip to main content

The Zohydro Controversy: Modern Day (Part II)





In modern day pain medicine, many of the same historic controversies exist.


Addiction is a prevalent problem in society; sometimes it emerges when a patient is ordered pain medication for a legitimate purpose, only to fall victim to a bigger problem  Other times, people who are somehow predisposed to substance abuse find themselves drawn to it for recreation purposes.  In either case, once addicted, the problem is the same for all of these individuals.

Modern addiction medicine does not employ withdrawal or detoxification as part of treatment; it seems more common to send these persons to day programs or inpatient treatment and prescribe suboxone or some similar agent for maintenance purposes. My biggest problem with this approach is that the problem is not really fixed--it's only patched. You see, suboxone and its nearest relatives merely trick the body's opiate receptors into thinking that all is well.

In my work career, I witnessed this problem many times over.  The saddest situations were those where young pregnant women, once addicts, went through rehab only to emerge on one of these maintenance drugs. When their children came into the world, they were born addicted. There were other patients on high dose chronic pain medications or maintenance medication such as suboxone or methadone. At times, pain management was very difficult for these persons.

The FDA's latest efforts with regard to pain medications involves something they call REMS strategy.
This strategy aims to evaluate the risk of abuse potential before drugs with abuse potential are prescribed, and attempt to control the number of abusers in the population.  The success of this program remains to be seen.

Meanwhile, a new long acting opioid, Zohydro, has come onto the marketplace. Zohydro is the controlled release version of hydrocodone.  It was FDA approved in late 2013. While it seems that this product has great potential to help those with chronic pain, it sure has its share of critics. This stems from the fact that short acting products containing hydrocodone have high abuse potential. Why would Zohydro be any different?

In addition to regulations by the FDA, DEA, State Boards of Medicine, Dentistry, Pharmacy, etc. local governments are attempting chime in with their own regulations regarding opioids.  For instance, back in 2013, while Mayor Bloomberg was still in office--he set out to regulate the use of these medications in Emergency Rooms across NYC.   Similar rulings have been adopted in Washington State and Utah.
Now, with the latest drug--Zohydro--there is news of regulation in Massachusetts and hearings are underway in Pennsylvania.

Meanwhile, there are many stories about heroin usage on the rise.  It seems like the more things change, the more they stay the same. One has to wonder what the future holds for those who suffer from addiction and those who suffer from chronic pain.

Sources: FDA, Washington Times, Masslive, Fox43, Time,Pixabay






Sources: FDA,

Comments

Popular posts from this blog

Living with Chronic pain hits the big screen!

Been to the movies lately?  Jennifer Aniston is on the big screen in a recent release titled "Cake."
Her character, Claire is a victim of chronic pain...she belongs to a support group, where all of the members are coming to terms with the suicide of one of their members.  Of course, she also takes pain medication and addiction is another of her problems...and of course there's more!

I guess I am writing this post just to bring readers' attention to the fact that Hollywood has become aware of the crisis that is chronic pain.  This movie is a testament to that. People that don't have to live with this kind of pain don't fully understand the whole story.  Maybe this movie will shed some light on the issues.

Here is the official trailer for the movie:


Sources: prweb;NorthJersey.com;YouTube


Herpes As A Helper?

If you've ever had shingles, or known anyone that has experienced it, you probably know that chronic pain can persist following the initial attack (post herpetic neuralgia).  This is because the herpes virus seems to have an affinity for nerve cells.  And while it's not fun to have shingles or post herpetic neuralgia, the herpes virus may be a key in future development of delivery systems for pain management treatments.





Here's the deal--since Herpes simplex has an affinity for nerve cells, researchers are looking a genetically modified, safer version of the virus to deliver genetic material to damaged nerves.  In simple terms, once the genetic material reaches these nerve cells, it will hopefully encode these nerves to ultimately inhibit pain signals.  Animal studies and clinical trials in cancer patients have been encouraging thus far.

This is one of those developments that makes me believe that there is hope for those in chronic pain. Along with so many other exciting d…

The Knee Bone's Connected To The Leg Bone....

Two recent studies have brought a not-so-novel concept into the limelight-the concept being that people who present with knee pain often develop pain in other parts of their bodies.  These studies, known as the Multicenter Osteoarthritis Study (MOST) and the Osteoarthritis Initiative (OAI), were assessed by a Clinical Epidemiology Team as Boston University School of Medicine in an effort to find preventive strategies to combat this trend.




The authors suggest that knee pain may cause individuals to alter their gait in an effort to compensate for their discomfort. In doing so, the alignment of other body joints is altered, and this may be the cause of secondary joint pain, especially hips and ankles. The authors go on to say that the pain in these secondary sites is not necessarily osteoarthritis--perhaps bursitis or some other injury.

Osteoarthritis is a result of wear and tear in the joints.  We may not be able to completely eliminate osteoarthritis from occurring, but some common se…